TAMPA, Fla.--(BUSINESS WIRE)--Aug. 23, 2006--Nanobac Pharmaceuticals, Inc. (OTCBB:NNBP) (“Nanobac” or “the Company”) today announced that it has entered into an agreement and started work on an animal model to validate a proof of concept that calcifying nanoparticles (CNPs), also known as nanobacteria, promote gallstones.
